HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model‐based cost‐effectiveness
Open Access
- 15 September 2008
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 124 (4) , 970-978
Abstract
We evaluated the cost‐effectiveness of HPV16/18 vaccination for girls aged 12 years in The Netherlands in addition to cervical cancer screening. For this purpose, we developed a simulation model that describes the relation between each of the high‐risk human papillomavirus (hrHPV) types and cervical disease, allowing the occurrence of multiple type‐specific infections. Model parameters were derived from Dutch cohort studies, including a large population‐based screening trial, and from the national cervical cancer registry. The model satisfactorily reproduced Dutch data on HPV infection and the presence of cervical lesions. For our base‐case scenario in which 85% of the girls aged 12 years were vaccinated against types 16/18 (95% efficacy, lifelong protection), the model predicted a decrease of 60% in the number of cervical cancer cases and cervical cancer deaths indicating that substantial health benefits can be achieved. Health savings were robust against changes in the vaccine efficacy (varied from 85% to 98%) but savings showed a substantial reduction when the efficacy started waning 10 years after vaccination. The discounted costs per quality‐adjusted life year (QALY) were € 19,500/QALY (range € 11,000 to € 25,000/QALY) and lied near the cost‐effectiveness threshold of € 20,000/QALY used in The Netherlands. The simulations further showed that vaccination cannot replace screening because vaccination without screening was less effective than screening in preventing cancer in women over 40 years of age. In conclusion, our model results support the implementation of HPV16/18 vaccination in young women in addition to cervical cancer screening.Keywords
This publication has 48 references indexed in Scilit:
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialThe Lancet, 2007
- Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trialsThe Lancet, 2007
- Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineVaccine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialThe Lancet, 2006
- Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 VaccineJNCI: Journal of the National Cancer Institute, 2004
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI: Journal of the National Cancer Institute, 1995